NeoGenesis Pharmaceuticals, Inc. Names New Chief Executive Officer 
10/19/2005 5:10:16 PM

CAMBRIDGE, Mass., March 3 /PRNewswire/ -- NeoGenesis Pharmaceuticals, a privately held biotechnology company focused on applying novel screening and chemistry technologies to discover and develop small molecule drugs, today announced the appointment of Henry B. Skinner, Ph.D. as president and chief executive officer (CEO). Skinner, who was also elected to serve on the board of directors, succeeds Satish Jindal, Ph.D., who has been named chairman of the board and chief scientific officer (CSO).

"Henry Skinner brings leadership, energy and a demonstrated track record of success to this position," said Jindal. "Henry has demonstrated the ability to establish and grow productive relationships with key decision makers both within the company and at the collaborator level. His team building and strategic planning skills are highly valued at NeoGenesis, and I will continue my close collaboration with Henry to ensure a seamless transition."

"I am truly excited about this opportunity and challenge," said Skinner. "NeoGenesis is a unique drug discovery company with a great deal to offer. Its core technology, the Automated Ligand Identification System (ALIS), combined with its huge library of medicinally relevant compounds provides a powerful engine for rapid, efficient drug discovery. Most importantly, the company has a talented, dedicated team of professionals who make it all happen. In addition, the company has a strong working relationship with its many partners and collaborators. I look forward to leading NeoGenesis to its next level of growth and success."

Prior to joining NeoGenesis in September 2003 as chief business officer, Skinner was senior director, technology acquisitions and operations at Pfizer, leading the external research technology portfolio and strategy for worldwide research and development for Pharmacia Corporation. Earlier, Skinner served as director, business development at Lexicon Genetics Incorporated where he provided strategic direction and planning for an aggressive program of establishing collaborations, alliances and in-licensing opportunities.

Skinner earned a bachelor's degree and master's degree in biology/biotechnology from Worcester Polytechnic Institute. He also earned a master's degree in biochemistry and a Ph.D. in microbiology at the University of Illinois-Urbana-Champaign, and completed a postdoctoral program in molecular and human genetics at Baylor College of Medicine. Skinner has also received a number of awards and honors related to breast cancer research and neuromuscular disease research, as well as biology and biotechnology.

About NeoGenesis Pharmaceuticals, Inc.

NeoGenesis Pharmaceuticals, Inc. is a drug discovery company focused on using its proprietary drug discovery technologies to discover and develop a portfolio of small molecule-based drugs, both for itself and for its collaboration partners. The company's universal, unbiased, affinity-based technologies, coupled with its library of millions of diverse medicinally relevant compounds, provide an unmatched efficiency in lead discovery and optimization. NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid and universal affinity-based system for identifying and optimizing novel drug leads. Coupled with the company's NeoMorph compound library, consisting of more than 10 million diverse medicinally relevant small molecules, ALIS enables the identification of novel and selective drug leads against validated and emerging new genomic targets. Founded in 1997 and headquartered in Cambridge, Massachusetts, NeoGenesis has developed partnerships and collaborative research agreements with many of the world's leading biotechnology and pharmaceutical companies, including: Aventis, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering- Plough and Tularik. Additional information about NeoGenesis may be found on the company's website at

Note: NeoGenesis, ALIS and NeoMorph are trademarks of NeoGenesis Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

NeoGenesis Pharmaceuticals, Inc.

CONTACT: Henry B. Skinner, Ph.D., President & CEO of NeoGenesisPharmaceuticals, Inc., +1-617-588-5179; or Bill Monigle, IR/PR Counsel forNeoGenesis Pharmaceuticals, Inc., +1-603-424-1184